The NIH pulse cyclophosphamide regime: The end of an era?

Lupus

Volumn 13, Issue 1, 2004, Pages 1-3

  Karim, Y ^a   D'Cruz, D P ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

AMENORRHEA AND OLIGOMENORRHEA; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG CHOICE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; EDITORIAL; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LEUKOPENIA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAINTENANCE THERAPY; MORTALITY; NONHUMAN; OVARY INSUFFICIENCY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REMISSION;

CLINICAL TRIALS; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; NATIONAL INSTITUTES OF HEALTH (U.S.); UNITED STATES;

EID: 1642501086     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203304lu524ed     Document Type: Editorial

References (16)

1. Austin HA III, Klippel JH, Balow JE et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-619.
2. Martin-Suarez I, D'Cruz D, Mansoor M, Fernandes AP, Khamashta MA, Hughes GRV. Immunosuppressive treatment in severe connective tissue diseases: effects of low dose intravenous cyclophosphamide. Ann Rheum Dis 1997; 56: 481-487.
3. D'Cruz D, Cuadrado MJ, Mujic F et al. Immunosuppressive therapy in lupus nephritis. Clin Exp Rheumatol 1997; 15: 275-282.
4. Houssiau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial. A randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-2131.
5. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997; 51: 1188-1195.
6. Illei GG, Takada K, Parkin D et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46: 995-1002.
7. Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. QJM 2000; 93: 15-20.
8. Corna D, Morigi M, Facchinetti D, Bertani T, Zoja C, Remuzzi G. Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney Int 1997; 51: 1583-1589.
9. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85-118.
10. Adu D, Cross J, Jayne DR. Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 2001; 10: 203-208.
11. Moder KG. Mycophenolate mofetil: new applications for this immunosuppressant. Ann Allergy Asthma Immunol 2003; 90: 15-19.
12. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343: 1156-1162.
13. Ginzler EM, Aranow C, Buyon J et al. A mulicenter study of mycophenolate mofetil (MMF) vs. intravenous cyclophosphamide (IVC) as induction therapy for severe lupus nephritis (LN): preliminary results. Arthritis Rheum 2003; 48: S647.
14. Contreras G, Pardo V, Leclercq B et al. Lupus nephritis: sequential therapy with short-term intravenous cyclophosphamide followed by maintenance oral mycophenolate mofetil or oral azathioprine is more efficacious and safer than long-term intravenous cyclophosphamide. American Society of Nephrology Annual Meeting 2003.
15. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GR. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford) 2002; 41: 876-882.
16. Cellcept (mycophenolate mofetil). Complete product information. Roche Laboratories Inc. Revised December 2000.